2016
DOI: 10.1186/s13287-016-0295-2
|View full text |Cite
|
Sign up to set email alerts
|

Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model

Abstract: BackgroundStem cell therapy can be used for alleviating the neuropathic pain induced by spinal cord injuries (SCIs). However, survival and differentiation of stem cells following their transplantation vary depending on the host and intrinsic factors of the cell. Therefore, the present study aimed to determine the effect of stem cells derived from bone marrow (BM-MSC) and umbilical cord (UC-MSC) on neuropathic pain relief.MethodsA compression model was used to induce SCI in a rat model. A week after SCI, about … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
74
0
2

Year Published

2016
2016
2019
2019

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 113 publications
(79 citation statements)
references
References 82 publications
3
74
0
2
Order By: Relevance
“…Due to these advantages, UC-MSCs are being explored as a promising candidate for many potential clinical applications. Recent studies have provided encouraging results regarding the utility of UC-MSCs in several disease models, such as rescuing visual functions in a rodent model of retinal disease14, alleviating neuropathic pain15, protect against experimental colitis16 and treating rat liver fibrosis1718. The use of UC-MSCs as a cellular therapy is currently being explored in clinical trials, including for the treatment of GvHD1920.…”
mentioning
confidence: 99%
“…Due to these advantages, UC-MSCs are being explored as a promising candidate for many potential clinical applications. Recent studies have provided encouraging results regarding the utility of UC-MSCs in several disease models, such as rescuing visual functions in a rodent model of retinal disease14, alleviating neuropathic pain15, protect against experimental colitis16 and treating rat liver fibrosis1718. The use of UC-MSCs as a cellular therapy is currently being explored in clinical trials, including for the treatment of GvHD1920.…”
mentioning
confidence: 99%
“…The efficacy of the treatment changes with the administration time and repeats of application of MSCs during an injury [40].…”
Section: Discussionmentioning
confidence: 99%
“…38,71,7377 These physiologic effects can additionally be accentuated with the co-administration of various growth factors, to include brain-derived neutrophic factor, 71 glial cell-line neutrophic factor, 72 and neurotrophin-3. 78 …”
Section: Methodsmentioning
confidence: 99%